These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 24932302)

  • 1. Usefulness of short-term eltrombopag treatment as a supportive treatment in hepatocellular carcinoma patients with cirrhosis and severe thrombocytopenia: A report of two cases.
    Kawaguchi T; Nakano M; Satani M; Sumie S; Yamada S; Amano K; Kuromatsu R; Sata M
    Oncol Lett; 2014 Jun; 7(6):2130-2134. PubMed ID: 24932302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.
    Kühne T; Imbach P
    Ann Hematol; 2010 Jul; 89 Suppl 1():67-74. PubMed ID: 20405290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
    Afdhal NH; Dusheiko GM; Giannini EG; Chen PJ; Han KH; Mohsin A; Rodriguez-Torres M; Rugina S; Bakulin I; Lawitz E; Shiffman ML; Tayyab GU; Poordad F; Kamel YM; Brainsky A; Geib J; Vasey SY; Patwardhan R; Campbell FM; Theodore D
    Gastroenterology; 2014 Feb; 146(2):442-52.e1. PubMed ID: 24126097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dental procedures in 24 patients with chronic immune thrombocytopenia in prospective clinical studies of eltrombopag.
    Tarantino MD; Fogarty PF; Shah P; Brainsky A
    Platelets; 2015; 26(1):93-6. PubMed ID: 24433306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.
    Afdhal NH; Giannini EG; Tayyab G; Mohsin A; Lee JW; Andriulli A; Jeffers L; McHutchison J; Chen PJ; Han KH; Campbell F; Hyde D; Brainsky A; Theodore D;
    N Engl J Med; 2012 Aug; 367(8):716-24. PubMed ID: 22913681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease.
    Khemichian S; Terrault NA
    Semin Thromb Hemost; 2020 Sep; 46(6):682-692. PubMed ID: 32820479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eltrombopag: a novel oral thrombopoietin receptor agonist.
    Corman SL; Mohammad RA
    Ann Pharmacother; 2010 Jun; 44(6):1072-9. PubMed ID: 20460556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
    Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D
    Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.
    Cheng G; Saleh MN; Marcher C; Vasey S; Mayer B; Aivado M; Arning M; Stone NL; Bussel JB
    Lancet; 2011 Jan; 377(9763):393-402. PubMed ID: 20739054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.
    Bussel JB; Provan D; Shamsi T; Cheng G; Psaila B; Kovaleva L; Salama A; Jenkins JM; Roychowdhury D; Mayer B; Stone N; Arning M
    Lancet; 2009 Feb; 373(9664):641-8. PubMed ID: 19231632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
    Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
    Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia.
    Garnock-Jones KP
    BioDrugs; 2011 Dec; 25(6):401-4. PubMed ID: 22050343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia.
    Garnock-Jones KP
    Drugs; 2011 Jul; 71(10):1333-53. PubMed ID: 21770480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
    Dodillet H; Kreuzer KA; Monsef I; Skoetz N
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009883. PubMed ID: 28962071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful resection of intrahepatic cholangiocarcinoma with idiopathic thrombocytopenic purpura using thrombopoietin receptor agonist: a case report.
    Hoshino K; Harimoto N; Muranushi R; Araki K; Yamanaka T; Hagiwara K; Ishii N; Tsukagoshi M; Igarashi T; Tanaka H; Watanabe A; Kubo N; Yokobori T; Shirabe K
    Surg Case Rep; 2019 Apr; 5(1):56. PubMed ID: 30969381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of eltrombopag, a thrombopoietin receptor agonist, in post-transplantation thrombocytopenia.
    Reid R; Bennett JM; Becker M; Chen Y; Milner L; Phillips GL; Liesveld J
    Am J Hematol; 2012 Jul; 87(7):743-5. PubMed ID: 22573520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-life experience of lusutrombopag for cirrhotic patients with low platelet counts being prepared for invasive procedures.
    Takada H; Kurosaki M; Nakanishi H; Takahashi Y; Itakura J; Tsuchiya K; Yasui Y; Tamaki N; Takaura K; Komiyama Y; Higuchi M; Kubota Y; Wang W; Okada M; Shimizu T; Watakabe K; Enomoto N; Izumi N
    PLoS One; 2019; 14(2):e0211122. PubMed ID: 30768601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eltrombopag Dose Adjustment During Infection-Induced Thrombocytosis in a Patient With Chronic Idiopathic Thrombocytopenic Purpura.
    Ahmed M; Abdelmahmuod E; Ali EA; Yassin MA
    Cureus; 2021 Mar; 13(3):e14166. PubMed ID: 33936878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States.
    Tremblay G; Dolph M; Roy AN; Said Q; Forsythe A
    Clin Ther; 2020 May; 42(5):860-872.e8. PubMed ID: 32199608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eltrombopag for treatment of thrombocytopenia-associated disorders.
    Merli P; Strocchio L; Vinti L; Palumbo G; Locatelli F
    Expert Opin Pharmacother; 2015; 16(14):2243-56. PubMed ID: 26364898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.